Effects of celecoxib on hematoma and edema volumes in primary intracerebral
hemorrhage: a multicenter randomized controlled trial.
Author(s): Lee SH(1), Park HK, Ryu WS, Lee JS, Bae HJ, Han MK, Lee YS, Kwon HM, Kim CK, Park
ES, Chung JW, Jung KH, Roh JK.
Affiliation(s): Author information:
(1)Department of Neurology, Seoul National University Hospital, Seoul, Korea.
Publication date & source: 2013, Eur J Neurol. , 20(8):1161-9
BACKGROUND AND PURPOSE: We investigated the effect of celecoxib, a selective
inhibitor of cyclo-oxygenase 2, in patients with intracerebral hemorrhage (ICH).
METHODS: We conducted a multicenter, randomized, controlled, and open with
blinded end-point trial of 44 Korean patients 18 years or older with ICH within
24 h of onset. The intervention group (n = 20) received celecoxib (400 mg twice a
day) for 14 days. The control group (n = 24) received the standard medical
treatment for ICH. The primary end-point was the number of patients with a change
in the volume of perihematomal edema (PHE) from the 1st to the 7th ± 1 day
(cut-off value, 20%).
RESULTS: The time from onset to computed tomography scan slightly differed
between groups (177 ± 160 min for control vs. 297 ± 305 min for the celecoxib
group; P = 0.10). In the primary end-point analysis using cut-off values, there
was a significant shift to reduced expansion of PHE in the celecoxib group (P =
0.005). With respect to the secondary end-points, there was also a significant
shift to reduced expansion of ICH in the celecoxib group (P = 0.046). In
addition, the expansion rate of PHE at follow-up tended to be higher in the
control group than in the celecoxib group (90.6 ± 91.7% vs. 44.4 ± 64.9%; P =
0.058).
CONCLUSIONS: In our small, pilot trial, administration of celecoxib in the acute
stage of ICH was associated with a smaller expansion of PHE than that observed in
controls.
|